<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075829</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN0102</org_study_id>
    <secondary_id>BMT CTN 0102</secondary_id>
    <secondary_id>SUMC-79730</secondary_id>
    <secondary_id>417</secondary_id>
    <nct_id>NCT00075829</nct_id>
    <nct_alias>NCT00321607</nct_alias>
    <nct_alias>NCT00386568</nct_alias>
  </id_info>
  <brief_title>Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)</brief_title>
  <official_title>A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a Phase III, multi-center trial of tandem autologous transplants
      versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling
      non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the
      appropriate arm depending on the availability of an HLA-matched sibling. There is a nested
      randomized phase III trial of observation versus maintenance therapy following the second
      autologous transplant for patients on the tandem autologous transplant arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma (MM), characterized by malignant plasma cell proliferation, bone
      destruction, and immunodeficiency, is a disease with a median age at diagnosis of
      approximately 65 years. It is responsible for about 1 percent of all cancer-related deaths in
      Western Countries. Conventional treatments with chemotherapy and radiation therapy are
      non-curative but improve quality of life and duration of survival. Attempts to cure myeloma
      through high-dose therapy followed by autografting or allografting have largely failed due to
      a combination of relapsed disease or transplant related mortality (TRM). High-dose therapy
      with autologous transplantation is safe and has low TRM (less than 5%), but is associated
      with a continuing and nearly universal risk of disease progression and relapse. Even so,
      autologous transplantation is superior to continued conventional chemotherapy. Recent data
      indicate that tandem autologous transplants are superior to a single procedure. Even with
      this approach, patients remain at risk of relapse and additional approaches are needed.

      DESIGN NARRATIVE:

      The overall study design is that of biologic assignment, based on the availability of an
      HLA-matched sibling, to one of two treatment strategies for MM patients. Patients without an
      HLA-matched sibling will undergo tandem autologous transplants. Patients with an HLA-matched
      sibling will undergo an autologous transplant followed by a non-myeloablative allogeneic
      transplant. In addition, the tandem autologous transplant recipients will be randomized to
      either observation or one year of maintenance therapy to begin following the second
      autologous transplant. The large number of MM patients without an HLA-matched sibling enables
      us to evaluate the role of maintenance therapy following tandem autologous transplants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Year 3</time_frame>
    <description>Patients are considered a failure for this endpoint if they die or if they progress or relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) for Standard Risk</measure>
    <time_frame>Years 1, 2, and 3</time_frame>
    <description>The event is death from any cause, patients alive at the time of last observation are considered censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) for High Risk</measure>
    <time_frame>Year 3</time_frame>
    <description>The event is death from any cause, patients alive at the time of last observation are considered censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Progression/Relapse</measure>
    <time_frame>Year 3</time_frame>
    <description>Patients are considered experiencing an event when they progress. Deaths without progression are considered as a competing risk. Patients initiating non-protocol anti-myeloma therapy are considered to have progressed on this protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Treatment Related Mortality (TRM)</measure>
    <time_frame>Year 3</time_frame>
    <description>TRM is defined as death occurring in a patient from causes other than relapse or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interval From First to Second Transplantation</measure>
    <time_frame>Year 1</time_frame>
    <description>Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients will receive a second transplant according to treatment assignments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of Graft Versus Host Disease (GVHD)</measure>
    <time_frame>Day 100</time_frame>
    <description>Incidence and severity of GVHD will be scored according to the BMT clinical trials network Manual of Procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of Chronic GVHD</measure>
    <time_frame>Years 1 and 2</time_frame>
    <description>Incidence and severity of chronic GVHD will be scored according to the BMT clinical trials network Manual of Procedures.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">710</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Auto transplants plus Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One autologous transplant along with a second autologous transplant will be preformed followed by one year of Dexamethasone and Thalidomide maintenance therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Auto transplants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One autologous transplant along with a second autologous transplant will be preformed followed by one year of observation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Auto and Allo transplants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One autologous transplant and one non-myeloablative allogeneic transplant will be preformed and followed by one year of observation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>One Autologous Transplant</intervention_name>
    <description>Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive ~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) &gt; 500/mm3 for two days.</description>
    <arm_group_label>Auto transplants plus Therapy</arm_group_label>
    <arm_group_label>Auto transplants</arm_group_label>
    <arm_group_label>Auto and Allo transplants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Non-Myeloablative Allogeneic Transplant</intervention_name>
    <description>Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.</description>
    <arm_group_label>Auto and Allo transplants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Second Autologous Transplant</intervention_name>
    <description>Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.</description>
    <arm_group_label>Auto transplants plus Therapy</arm_group_label>
    <arm_group_label>Auto transplants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.</description>
    <arm_group_label>Auto transplants plus Therapy</arm_group_label>
    <other_name>Thalomid™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.</description>
    <arm_group_label>Auto transplants plus Therapy</arm_group_label>
    <other_name>Decadron, DexPak</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>One year of observation post-transplants.</description>
    <arm_group_label>Auto transplants</arm_group_label>
    <arm_group_label>Auto and Allo transplants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meeting the Durie and Salmon criteria for initial diagnosis of MM

          -  Stage II or III MM at diagnosis or anytime thereafter

          -  Symptomatic MM requiring treatment at diagnosis or anytime thereafter

          -  Received at least three cycles of initial systemic therapy and are within 2-10 months
             of initiation of the initial therapy (this time frame excludes the time for
             mobilization therapy)

          -  If receiving chemotherapy-based mobilization regimens, must be able to receive
             high-dose melphalan between 2 and 8 weeks after the initiation of mobilization therapy
             whether delivered at the transplant center or at a referring center

          -  Adequate organ function as measured by:

               1. Cardiac: Left ventricular ejection fraction at rest greater than 40%

               2. Hepatic: Bilirubin less than 2 times the upper limit of normal and alanine
                  transaminase (ALT) and aspartate transaminase (AST) less than 3 times the upper
                  limit of normal

               3. Renal: Creatinine clearance greater than 40 ml/min (measured or
                  calculated/estimated)

               4. Pulmonary: Carbon monoxide diffusion (DLCO), Volume forcibly exhaled in one
                  second (FEV1), and Forced Vital Capacity (FVC) greater than 50% of predicted
                  value (corrected for hemoglobin), or O2 saturation greater than 92% of room air

          -  An adequate autologous graft defined as a cryopreserved PBSC graft containing at least
             4.0 x 106 CD34+ cells/kg patient weight; if prior to enrollment it is known that a
             patient will be on the auto-allo arm (i.e., a consenting, eligible HLA-matched sibling
             donor is available), the required autograft must contain at least 2.0 x 10^6 CD34+
             cells/kg patient weight; the graft may not be CD34+ selected or otherwise manipulated
             to remove tumor or other cells; the graft can be collected at the transplanting
             institution or by a referring center; for patients without an HLA-matched sibling
             donor, the autograft must be stored so that there are two products each containing at
             least 2 x 10^6 CD34+ cells/kg patient weight

        Exclusion Criteria:

          -  Never advanced beyond Stage I MM since diagnosis

          -  Non-secretory MM (absence of a monoclonal protein [M protein] in serum as measured by
             electrophoresis and immunofixation and the absence of Bence Jones protein in the urine
             defined by use of conventional electrophoresis and immunofixation techniques)

          -  Plasma cell leukemia

          -  Karnofsky performance score less than 70%, unless approved by the Medical Monitor or
             one of the Protocol Chairs

          -  Uncontrolled hypertension

          -  Uncontrolled bacterial, viral, or fungal infections (currently taking medication and
             progression of clinical symptoms)

          -  Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma
             in situ; cancer treated with curative intent less than 5 years previously will not be
             allowed unless approved by the Medical Monitor or one of the Protocol Chairs; cancer
             treated with curative intent more than 5 years previously will be allowed

          -  Pregnant or breastfeeding

          -  Seropositive for the human immunodeficiency virus (HIV)

          -  Unwilling to use contraceptive techniques during and for 12 months following treatment

          -  Prior allograft or prior autograft

          -  Received mid-intensity melphalan (more than 50 mg IV) as part of prior therapy

          -  Prior organ transplant requiring immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Samaritan</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic/Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-1027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine (Shands)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-100277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BMT Group of Georgia/Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IBMT (Indiana Blood and Marrow Transplant) at St Francis Franciscan Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wichita CCOP</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts - New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFCI/Brigham &amp; Women's</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital BMT Program</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland/Case Western</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University (A)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase - Temple University - BMT Program</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2442</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah BMT/Univ of Utah Med School</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University MCV Hospitals</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospitals &amp; Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://web.emmes.com/study/bmt2/index.html</url>
    <description>Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <link>
    <url>https://bethematch.org/</url>
    <description>National Marrow Donor Program</description>
  </link>
  <results_reference>
    <citation>Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG; Blood Marrow Transplant Clinical Trials Network (BMT CTN). Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011 Dec;12(13):1195-203. doi: 10.1016/S1470-2045(11)70243-1. Epub 2011 Sep 29.</citation>
    <PMID>21962393</PMID>
  </results_reference>
  <results_reference>
    <citation>Logan B, Leifer E, Bredeson C, Horowitz M, Ewell M, Carter S, Geller N. Use of biological assignment in hematopoietic stem cell transplantation clinical trials. Clin Trials. 2008;5(6):607-16. doi: 10.1177/1740774508098326.</citation>
    <PMID>19029209</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2004</study_first_posted>
  <results_first_submitted>December 17, 2014</results_first_submitted>
  <results_first_submitted_qc>June 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2016</results_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage II Multiple Myeloma</keyword>
  <keyword>Stage III Multiple Myeloma</keyword>
  <keyword>Refractory Plasma Cell Neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>BMT CTN-0102</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/bmtctn0102/</doc_url>
      <doc_comment>NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local Institutional Review Board (IRB) approval or certification of exemption from IRB review, and completion of a data use agreement.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>BMT CTN-0102</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/bmtctn0102/</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>BMT CTN-0102</doc_id>
      <doc_type>Study Forms</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/bmtctn0102/</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled between December 2003 and March 2007 from 37 different transplant centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Auto-Auto Standard Risk</title>
          <description>Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for standard risk patients PFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled for analysis.</description>
        </group>
        <group group_id="P2">
          <title>Auto-Allo Standard Risk</title>
          <description>Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients</description>
        </group>
        <group group_id="P3">
          <title>Auto-Auto High Risk</title>
          <description>Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for high risk patients
PFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled for analysis.</description>
        </group>
        <group group_id="P4">
          <title>Auto-Allo High Risk</title>
          <description>Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="436"/>
                <participants group_id="P2" count="189"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="178">Participants that were alive and free of disease progression at the end of follow-up (3 years)</participants>
                <participants group_id="P2" count="71">Participants that were alive and free of disease progression at the end of follow-up (3 years)</participants>
                <participants group_id="P3" count="14">Participants that were alive and free of disease progression at the end of follow-up (3 years)</participants>
                <participants group_id="P4" count="13">Participants that were alive and free of disease progression at the end of follow-up (3 years)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="118"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis is based on intention-to-treat data. Primary analysis of the clinical trial focused on patients meeting protocol criteria of standard risk multiple myeloma.</population>
      <group_list>
        <group group_id="B1">
          <title>Auto-Auto Standard Risk</title>
          <description>Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for standard risk patients
PFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled for analysis.</description>
        </group>
        <group group_id="B2">
          <title>Auto-Allo Standard Risk</title>
          <description>Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients</description>
        </group>
        <group group_id="B3">
          <title>Auto-Auto High Risk</title>
          <description>Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for high risk patients
PFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled for analysis.</description>
        </group>
        <group group_id="B4">
          <title>Auto-Allo High Risk</title>
          <description>Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="436"/>
            <count group_id="B2" value="189"/>
            <count group_id="B3" value="48"/>
            <count group_id="B4" value="37"/>
            <count group_id="B5" value="710"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="22" upper_limit="70"/>
                    <measurement group_id="B2" value="53" lower_limit="29" upper_limit="68"/>
                    <measurement group_id="B3" value="57" lower_limit="32" upper_limit="70"/>
                    <measurement group_id="B4" value="51" lower_limit="32" upper_limit="66"/>
                    <measurement group_id="B5" value="53.2" lower_limit="22" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="291"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="335"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance score</title>
          <description>Assesses patient self-perceived global quality of life and functioning (excellent, very good, good, fair, poor), where 100 equals perfect quality of life.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>100 - 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="344"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>β-2 Microglobulin</title>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" lower_limit="0.004" upper_limit="4.0"/>
                    <measurement group_id="B2" value="2.0" lower_limit="0.9" upper_limit="4.0"/>
                    <measurement group_id="B3" value="4.4" lower_limit="0.9" upper_limit="9.8"/>
                    <measurement group_id="B4" value="3.7" lower_limit="1.2" upper_limit="6.6"/>
                    <measurement group_id="B5" value="3.025" lower_limit="0.004" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Durie-Salmon</title>
          <description>The Durie and Salmon classification uses three multiple myeloma stages. Stage I has all of the following: Hemoglobin greater than 10 g/dL, Serum calcium less than 12 mg/dL, Normal bone structure or solitary plasmacytoma on radiographs, and Low M component. Stage II does not fit either Stage I or Stage III. Stage III has one or more of the following: Hemoglobin less than 8.5 g/dL, Serum calcium greater than 12 mg/dL, Advanced lytic bone lesions, and/or Hyper M component.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stages I-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="294"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Interval from diagnosis to transplantation</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="3" upper_limit="55"/>
                    <measurement group_id="B2" value="7" lower_limit="4" upper_limit="35"/>
                    <measurement group_id="B3" value="7" lower_limit="5" upper_limit="22"/>
                    <measurement group_id="B4" value="7" lower_limit="3" upper_limit="38"/>
                    <measurement group_id="B5" value="7" lower_limit="3" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease status</title>
          <description>Disease status at time of first autologous transplantation represents the results from initial multiple myeloma therapy received prior to trial enrollment: Complete Response (CR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Near CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Good PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>Patients are considered a failure for this endpoint if they die or if they progress or relapse.</description>
        <time_frame>Year 3</time_frame>
        <population>Patients that completed second transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Auto-Auto Standard Risk</title>
            <description>Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients</description>
          </group>
          <group group_id="O2">
            <title>Auto-Allo Standard Risk</title>
            <description>Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients</description>
          </group>
          <group group_id="O3">
            <title>Auto-Auto High Risk</title>
            <description>Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients</description>
          </group>
          <group group_id="O4">
            <title>Auto-Allo High Risk</title>
            <description>Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>Patients are considered a failure for this endpoint if they die or if they progress or relapse.</description>
          <population>Patients that completed second transplant</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="42" upper_limit="51"/>
                    <measurement group_id="O2" value="43" lower_limit="36" upper_limit="51"/>
                    <measurement group_id="O3" value="33" lower_limit="22" upper_limit="50"/>
                    <measurement group_id="O4" value="40" lower_limit="27" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) for Standard Risk</title>
        <description>The event is death from any cause, patients alive at the time of last observation are considered censored.</description>
        <time_frame>Years 1, 2, and 3</time_frame>
        <population>Patients that completed second transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Auto-Auto Standard Risk</title>
            <description>Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients</description>
          </group>
          <group group_id="O2">
            <title>Auto-Allo Standard Risk</title>
            <description>Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) for Standard Risk</title>
          <description>The event is death from any cause, patients alive at the time of last observation are considered censored.</description>
          <population>Patients that completed second transplant</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="93" upper_limit="97"/>
                    <measurement group_id="O2" value="91" lower_limit="87" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="86" upper_limit="92"/>
                    <measurement group_id="O2" value="85" lower_limit="80" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="77" upper_limit="84"/>
                    <measurement group_id="O2" value="77" lower_limit="72" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) for High Risk</title>
        <description>The event is death from any cause, patients alive at the time of last observation are considered censored.</description>
        <time_frame>Year 3</time_frame>
        <population>Patients that completed second transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Auto-Auto High Risk</title>
            <description>Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients</description>
          </group>
          <group group_id="O2">
            <title>Auto-Allo High Risk</title>
            <description>Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) for High Risk</title>
          <description>The event is death from any cause, patients alive at the time of last observation are considered censored.</description>
          <population>Patients that completed second transplant</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="54" upper_limit="82"/>
                    <measurement group_id="O2" value="59" lower_limit="45" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Progression/Relapse</title>
        <description>Patients are considered experiencing an event when they progress. Deaths without progression are considered as a competing risk. Patients initiating non-protocol anti-myeloma therapy are considered to have progressed on this protocol.</description>
        <time_frame>Year 3</time_frame>
        <population>Patients that completed second transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Auto-Auto Standard Risk</title>
            <description>Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients</description>
          </group>
          <group group_id="O2">
            <title>Auto-Allo Standard Risk</title>
            <description>Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients</description>
          </group>
          <group group_id="O3">
            <title>Auto-Auto High Risk</title>
            <description>Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients</description>
          </group>
          <group group_id="O4">
            <title>Auto-Allo High Risk</title>
            <description>Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Progression/Relapse</title>
          <description>Patients are considered experiencing an event when they progress. Deaths without progression are considered as a competing risk. Patients initiating non-protocol anti-myeloma therapy are considered to have progressed on this protocol.</description>
          <population>Patients that completed second transplant</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="46" upper_limit="55"/>
                    <measurement group_id="O2" value="46" lower_limit="39" upper_limit="54"/>
                    <measurement group_id="O3" value="57" lower_limit="42" upper_limit="71"/>
                    <measurement group_id="O4" value="38" lower_limit="22" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Treatment Related Mortality (TRM)</title>
        <description>TRM is defined as death occurring in a patient from causes other than relapse or progression.</description>
        <time_frame>Year 3</time_frame>
        <population>Patients that completed second transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Auto-Auto Standard Risk</title>
            <description>Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients</description>
          </group>
          <group group_id="O2">
            <title>Auto-Allo Standard Risk</title>
            <description>Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients</description>
          </group>
          <group group_id="O3">
            <title>Auto-Auto High Risk</title>
            <description>Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients</description>
          </group>
          <group group_id="O4">
            <title>Auto-Allo High Risk</title>
            <description>Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Treatment Related Mortality (TRM)</title>
          <description>TRM is defined as death occurring in a patient from causes other than relapse or progression.</description>
          <population>Patients that completed second transplant</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="11" lower_limit="7" upper_limit="16"/>
                    <measurement group_id="O3" value="11" lower_limit="2" upper_limit="19"/>
                    <measurement group_id="O4" value="22" lower_limit="8" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interval From First to Second Transplantation</title>
        <description>Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients will receive a second transplant according to treatment assignments.</description>
        <time_frame>Year 1</time_frame>
        <population>Patients that completed second transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Auto-Auto Standard Risk</title>
            <description>Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients</description>
          </group>
          <group group_id="O2">
            <title>Auto-Allo Standard Risk</title>
            <description>Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients</description>
          </group>
          <group group_id="O3">
            <title>Auto-Auto High Risk</title>
            <description>Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients</description>
          </group>
          <group group_id="O4">
            <title>Auto-Allo High Risk</title>
            <description>Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients</description>
          </group>
        </group_list>
        <measure>
          <title>Interval From First to Second Transplantation</title>
          <description>Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients will receive a second transplant according to treatment assignments.</description>
          <population>Patients that completed second transplant</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="58" upper_limit="193"/>
                    <measurement group_id="O2" value="105" lower_limit="61" upper_limit="262"/>
                    <measurement group_id="O3" value="101" lower_limit="63" upper_limit="155"/>
                    <measurement group_id="O4" value="111" lower_limit="61" upper_limit="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidences of Graft Versus Host Disease (GVHD)</title>
        <description>Incidence and severity of GVHD will be scored according to the BMT clinical trials network Manual of Procedures.</description>
        <time_frame>Day 100</time_frame>
        <population>GVHD was only assessed on the Auto-Allo arm for standard risk patients that completed second transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Auto-Allo Standard Risk</title>
            <description>Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients</description>
          </group>
        </group_list>
        <measure>
          <title>Incidences of Graft Versus Host Disease (GVHD)</title>
          <description>Incidence and severity of GVHD will be scored according to the BMT clinical trials network Manual of Procedures.</description>
          <population>GVHD was only assessed on the Auto-Allo arm for standard risk patients that completed second transplant</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grades II-IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="19" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grades III-IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidences of Chronic GVHD</title>
        <description>Incidence and severity of chronic GVHD will be scored according to the BMT clinical trials network Manual of Procedures.</description>
        <time_frame>Years 1 and 2</time_frame>
        <population>GVHD was only assessed on the Auto-Allo arm for standard risk patients that completed second transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Auto-Allo Standard Risk</title>
            <description>Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients</description>
          </group>
        </group_list>
        <measure>
          <title>Incidences of Chronic GVHD</title>
          <description>Incidence and severity of chronic GVHD will be scored according to the BMT clinical trials network Manual of Procedures.</description>
          <population>GVHD was only assessed on the Auto-Allo arm for standard risk patients that completed second transplant</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="39" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="46" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3-years post-first transplant</time_frame>
      <desc>Serious adverse events are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event. Only unexpected adverse events were required to be reported through the adverse event system per protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Auto-Auto Standard Risk</title>
          <description>Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients</description>
        </group>
        <group group_id="E2">
          <title>Auto-Allo Standard Risk</title>
          <description>Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients</description>
        </group>
        <group group_id="E3">
          <title>Auto-Auto High Risk</title>
          <description>Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients</description>
        </group>
        <group group_id="E4">
          <title>Auto-Allo High Risk</title>
          <description>Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Engraftment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Viral cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Delayed engraftment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gallbladder operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>.2</frequency_threshold>
        <default_vocab>MedDRA v12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Angiosarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Mendizabal</name_or_title>
      <organization>The EMMES Corporation</organization>
      <phone>301-251-1161</phone>
      <email>amendizabal@EMMES.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

